Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Dr Reddys Laboratories Ltd (A - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
RDY
New York
2834
https://www.drreddys.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Dr Reddys Laboratories Ltd (A
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
- Mar 22nd, 2024 11:00 am
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
- Mar 19th, 2024 11:00 am
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
- Feb 28th, 2024 2:40 pm
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
- Feb 5th, 2024 2:50 pm
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
- Feb 2nd, 2024 2:45 pm
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript
- Feb 1st, 2024 4:01 pm
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
- Feb 1st, 2024 2:03 pm
Dr. Reddy’s Q3 & 9M FY24 Financial Results
- Jan 31st, 2024 2:44 pm
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
- Jan 3rd, 2024 11:00 am
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
- Dec 14th, 2023 12:49 pm
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Dec 6th, 2023 12:00 pm
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
- Oct 30th, 2023 11:38 am
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript
- Oct 29th, 2023 5:08 pm
Dr. Reddy’s Q2 FY24 Financial Results
- Oct 27th, 2023 5:50 pm
All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy
- Oct 26th, 2023 4:00 pm
3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)
- Oct 4th, 2023 4:45 pm
Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Sep 26th, 2023 1:35 pm
Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now
- Sep 18th, 2023 4:45 pm
Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice
- Aug 31st, 2023 4:45 pm
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
- Aug 10th, 2023 11:00 am
Scroll